| Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents. | |
| | |
MedLine Citation:
|
PMID: 22876146 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Inhibitors of the vascular endothelial growth factor (vegf-is) signalling pathway have fundamentally changed the treatment of metastatic renal cell carcinoma (mrcc). Hypertension is one of the most common side effects of vegf-is and has been reported with almost every vegf-i used for treatment to date. The exact mechanism of vegf-i-induced hypertension appears complex and multifactorial, and it remains to be fully explained. No randomized clinical trials are available to guide the management of hypertension during vegf-i treatment in mrcc patients. The guiding principles suggested here summarize the consensus of opinions on the diagnosis and management of vegf-i-induced hypertension during treatment of mrcc obtained from an expert working group composed of 4 Canadian medical oncologists and 5 Canadian hypertension specialists. The Canadian Hypertension Education Program guidelines, available literature, and expert opinion were used to develop the guiding principles. |
| | |
Authors:
|
P Larochelle; C Kollmannsberger; R D Feldman; E L Schiffrin; L Poirier; F Patenaude; D Ruether; M Myers; G Bjarnason |
Related Documents
:
|
12643846 - K(atp) channel opener protects neonatal rabbit heart better than st. thomas' solution. 9689446 - Energy generation in hypertrophied postischemic myocardium. feasibility of prolonged in... 7186746 - Sensitivity of enzymatic release due to ischemia in the isolated rat heart. 1511466 - Cardiac sympathetic nervous activity during myocardial ischemia, reperfusion and ventri... 11106216 - Evaluation of a method for assessing respiratory mechanics during noninvasive ventilation. 17757066 - Crystal structures adopted by black phosphorus at high pressures. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current oncology (Toronto, Ont.) Volume: 19 ISSN: 1198-0052 ISO Abbreviation: Curr Oncol Publication Date: 2012 Aug |
Date Detail:
|
Created Date: 2012-08-09 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9502503 Medline TA: Curr Oncol Country: Canada |
Other Details:
|
Languages: eng Pagination: 202-8 Citation Subset: - |
Affiliation:
|
Institut de recherches cliniques de Montréal, Montreal, QC. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Outcomes of women with early-stage breast cancer receiving adjuvant trastuzumab.
Next Document: Psychosocial care for cancer: a framework to guide practice, and actionable recommendations for Onta...